

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-33 (canceled).

1 **Claim 34.** (currently amended): A pharmaceutical aerosol foam composition comprising:
2 petrolatum in an amount of approximately 10 to 50% by weight, based on the total weight
3 of the composition;
4 an aqueous solvent;
5 an organic cosolvent,
6 an effective amount of clobetasol ~~propionate~~ propionate, wherein said clobetasol
7 ~~propionate~~ propionate is solubilized in the composition.

1 **Claim 35.** (new): A pharmaceutical aerosol foam composition comprising:
2 an effective amount of a pharmaceutically active ingredient;
3 an occlusive agent;
4 an aqueous solvent;
5 an organic cosolvent; and
6 an emulsifier component in an amount wherein the ratio of emulsifier component to a
7 combination of the occlusive agent, pharmaceutically active ingredient, and organic cosolvent is
8 about 1:5 to about 1:8;
9 the pharmaceutically active ingredient being insoluble in both water and the occlusive
10 agent;
11 the occlusive agent being present in an amount sufficient to form an occlusive layer on
12 the skin, in use.

1 **Claim 36.** (new): The pharmaceutical aerosol foam composition according to **Claim 35**,
2 wherein the occlusive agent is petrolatum.

1 **Claim 37.** (new): The pharmaceutical foam composition according to **Claim 35** or **Claim**
2 **36**, wherein the water insoluble pharmaceutically active ingredient is selected from the group

3 consisting of an analgesic, anti-inflammatory agent, antifungal, antibacterial, anesthetic,
4 xanthine, sex hormone, antiviral, antipruritic, antihistamine and corticosteroid.

1 **Claim 38.** (new): The pharmaceutical aerosol foam composition according to **Claim 37**,
2 wherein the pharmaceutically active ingredient is a corticosteroid selected from the group
3 consisting of betamethasone valerate and clobetasol propionate.

1 **Claim 39.** (new): The pharmaceutical aerosol foam composition according to **Claim 35** or
2 **Claim 36**, wherein the pharmaceutically active ingredient is present in an amount of from
3 approximately 0.005% by weight to approximately 10% by weight, based on the total weight of
4 the pharmaceutical aerosol foam composition.

1 **Claim 40.** (new): The pharmaceutical aerosol foam composition according to **Claim 35**,
2 wherein the occlusive agent is selected from the group consisting of a mineral oil and grease, a
3 long chain acid, an animal fat and grease, a vegetable fat and grease and a water insoluble
4 polymer.

1 **Claim 41.** (new): The pharmaceutical aerosol foam composition according to **Claim 35** or
2 **Claim 36**, wherein the occlusive agent is present in an amount of approximately 55% by weight
3 or less, based on the total weight of the composition.

1 **Claim 42.** (new): The pharmaceutical aerosol foam composition according to **Claim 41**,
2 wherein the occlusive agent is present in an amount of approximately 10 to 50% by weight,
3 based on the total weight of the composition.

1 **Claim 43.** (new): The pharmaceutical aerosol foam composition according to **Claim 35** or
2 **Claim 36**, wherein the emulsifier component is selected from the group consisting of a non-
3 ionic, cationic or anionic surfactant, a fatty alcohol, a fatty acid and fatty acid salts thereof.

1 **Claim 44.** (new): The pharmaceutical aerosol foam composition according to **Claim 43**,
2 wherein the emulsifier component includes a mixture of a sorbitan ester and a polyoxyethylene
3 fatty alcohol ether.

1 **Claim 45.** (new): The pharmaceutical aerosol foam composition according to **Claim 35** or
2 **Claim 36**, wherein the emulsifier component is present in an amount of from approximately 1 to
3 15% by weight, based on the total weight of the composition.

1 **Claim 46.** (new): The pharmaceutical aerosol foam composition according to **Claim 35** or
2 **Claim 36**, wherein the aqueous solvent is present in an amount of from approximately 25 to 95%
3 by weight, based on the total weight of the composition.

1 **Claim 47.** (new): The pharmaceutical aerosol composition according to **Claim 35** or **Claim**
2 **36**, wherein the organic cosolvent is present in an amount from approximately 0.25% by weight
3 to 50% by weight, based on the total weight of the composition.

1 **Claim 48.** (new): The pharmaceutical aerosol foam composition according to **Claim 47**
2 wherein the organic cosolvent is an alkyl benzoate.

1 **Claim 49.** (new): The pharmaceutical aerosol foam composition according to **Claim 35** or
2 **Claim 36**, further including an effective amount of an aerosol propellant.

1 **Claim 50.** (new): The pharmaceutical aerosol foam composition according to **Claim 49**,
2 wherein the aerosol propellant is a hydrocarbon and is present in an amount of from
3 approximately 2.5 to 20% by weight, based on the total weight of the composition.

1 **Claim 51.** (new): A pharmaceutical aerosol dispenser comprising:
2 a pharmaceutical aerosol foam composition including
3 an effective amount of a pharmaceutically active ingredient;
4 an occlusive agent;
5 an aqueous solvent;
6 an organic cosolvent; and
7 an emulsifier component in an amount wherein the ratio of emulsifier component to a
8 combination of the occlusive agent, pharmaceutically active ingredient, and organic cosolvent is
9 about 1:5 to about 1:8;
10 the pharmaceutically active ingredient being insoluble in both water and the occlusive
11 agent;

12 the occlusive agent being present in an amount sufficient to form an occlusive layer on
13 the skin, in use.

1 **Claim 52.** (new): A pharmaceutical aerosol foam composition consisting essentially of:

2 an effective amount of a pharmaceutically active ingredient;

3 an occlusive agent;

4 an aqueous solvent;

5 an organic cosolvent; and

6 the pharmaceutically active ingredient being insoluble in both water and the occlusive
7 agent;

8 the occlusive agent being present in an amount sufficient to form an occlusive layer on
9 the skin, in use.

1 **Claim 53.** (new): The pharmaceutical aerosol foam composition according to **Claim 52**,
2 wherein the occlusive agent is petrolatum.

1 **Claim 54.** (new): The pharmaceutical foam composition according to **Claim 52** or **Claim**
2 **53**, wherein the water insoluble pharmaceutically active ingredient is selected from the group
3 consisting of an analgesic, an anti-inflammatory agent, an antifungal, an antibacterial, an
4 anesthetic, a xanthine, a sex hormone, an antiviral, an antipruritic, an antihistamine and a
5 corticosteroid.

1 **Claim 55.** (new): The pharmaceutical aerosol foam composition according to **Claim 37**,
2 wherein the pharmaceutically active ingredient is a corticosteroid selected from one or more of
3 the group consisting of betamethasone valerate and clobetasol propionate.

1 **Claim 56.** (new): The pharmaceutical aerosol foam composition according to **Claim 52** or
2 **Claim 53**, wherein the pharmaceutically active ingredient is present in amounts of from
3 approximately 0.005% by weight to approximately 10% by weight, based on the total weight of
4 the pharmaceutical aerosol foam composition.

1 **Claim 57.** (new): The pharmaceutical aerosol foam composition according to **Claim 52**,
2 wherein the occlusive agent is selected from the group consisting of a mineral oil and grease, a
3 long chain acid, an animal fat and grease, a vegetable fat and grease and a water insoluble
4 polymer.

1 **Claim 58.** (new): The pharmaceutical aerosol foam composition according to **Claim 52** or
2 **Claim 53**, wherein the occlusive agent is present in an amount of approximately 55% by weight
3 or less, based on the total weight of the composition.

1 **Claim 59.** (new): The pharmaceutical aerosol foam composition according to **Claim 58**,
2 wherein the occlusive agent is present in an amount of approximately 10 to 50% by weight,
3 based on the total weight of the composition.

1 **Claim 60.** (new): The pharmaceutical aerosol foam composition according to **Claim 52** or
2 **Claim 53**, further including an effective amount of an emulsifier component.

1 **Claim 61.** (new): The pharmaceutical aerosol foam composition according to **Claim 60**,
2 wherein the emulsifier component is selected from the group consisting of a non-ionic, cationic
3 or anionic surfactant, a fatty alcohol, a fatty acids and fatty acid salts thereof.

1 **Claim 62.** (new): The pharmaceutical aerosol foam composition according to **Claim 61**,
2 wherein the emulsifier component includes a mixture of a sorbitan ester and a polyoxyethylene
3 fatty alcohol ether.

1 **Claim 63.** (new): The pharmaceutical aerosol foam composition according to **Claim 60**,
2 wherein the emulsifier component is present in an amount of from approximately 1 to 15% by
3 weight, based on the total weight of the composition.

1 **Claim 64.** (new): The pharmaceutical aerosol foam composition according to **Claim 52** or
2 **Claim 53**, wherein the aqueous solvent is present in an amount of from approximately 25 to 95%
3 by weight, based on the total weight of the composition.

1 **Claim 65.** (new): The pharmaceutical aerosol composition according to **Claim 52** or **Claim**
2 **53**, wherein the organic cosolvent is present in an amount from approximately 0.25% by weight
3 to 50% by weight, based on the total weight of the composition.

1 **Claim 66.** (new): The pharmaceutical aerosol foam composition according to **Claim 65**
2 wherein the organic cosolvent is an alkyl benzoate.

1 **Claim 67.** (new): The pharmaceutical aerosol foam composition according to **Claim 52** or
2 **Claim 53**, further including an effective amount of an aerosol propellant.

1 **Claim 68.** (new): The pharmaceutical aerosol foam composition according to **Claim 67**,
2 wherein the aerosol propellant is a hydrocarbon and is present in an amount of from
3 approximately 2.5 to 20% by weight, based on the total weight of the composition.

1 **Claim 69.** (new): A pharmaceutical aerosol dispenser comprising a pharmaceutical aerosol
2 foam composition, said composition consisting essentially of:
3 an effective amount of a pharmaceutically active ingredient
4 an occlusive agent;
5 an aqueous solvent;
6 an organic cosolvent; and
7 the pharmaceutically active ingredient being insoluble in both water and the occlusive
8 agent;
9 the occlusive agent being present in an amount sufficient to form an occlusive layer on
10 the skin, in use.

1 **Claim 70.** (new): The pharmaceutical aerosol dispenser of **Claim 69**, wherein said foam
2 composition further includes an effective amount of an emulsifier component.

1 **Claim 71.** (new): A pharmaceutical aerosol foam composition comprising:
2 an effective amount of a corticosteroid;
3 an occlusive agent;
4 an aqueous solvent;

5 an organic cosolvent; and
6 the pharmaceutically active ingredient being insoluble in both water and the occlusive
7 agent;
8 the occlusive agent being present in an amount sufficient to form an occlusive layer on
9 the skin, in use.
10

1 **Claim 72.** (new) The pharmaceutical aerosol foam composition according to Claim 71,
2 further comprising an emulsifier component in an amount of from approximately 1 to 15% by
3 weight, based on the total weight of the composition.

1 **Claim 73.** (New): A pharmaceutical aerosol foam composition comprising:
2 an occlusive agent in an amount up to 50% by weight, based on the total weight of the
3 composition;
4 an aqueous solvent;
5 an organic cosolvent,
6 an effective amount of clobetasol propionate, wherein said clobetasol propionate is solubilized in
7 the composition.
